Is there an Indian targeted drug Vemurafenib?

The targeted drug Vemurafenib (Vemurafenib) does not have an Indian version of the original drug or generic version. There may be an original version of Vemurafenib sold in India. It is a highly selective mutant BRAF inhibitor that is very effective in patients with metastatic melanoma with BRAFV600 mutations (including patients with non-V600E mutations). Compared with traditional chemotherapy drugs, it can induce a remission rate of approximately 50% in patients and extend survival. In addition to its excellent clinical activity, vemurafenib is generally well tolerated, with the most common side effects being fatigue, arthralgia, and dermatitis.

The recommended dose of vemurafenib is 960 mg taken orally twice daily. The 50% inhibitory concentration of V600E was calculated to be 31 nmol/L, the estimated half-life was 50 hours, and the median time to peak plasma concentration was approximately 4 hours. Vemurafenib is highly bound to protein, and fat-rich meals will increase drug concentrations without affecting its mean terminal half-life. Despite the clinical success of vemurafenib, most (if not all) patients eventually develop drug resistance. Multiple resistance mechanisms have been identified, usually divided into MAPK pathway reactivation mechanisms (endogenous) and mechanisms outside the MAPK pathway (exogenous).

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.